[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533612":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":42,"responsibleParty":148,"collaborators":150,"id":159,"slug":160,"hasResults":161,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":12,"eligibilityCriteria":165,"healthyVolunteers":161,"sex":166,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":12,"studyType":172,"phases":173,"briefSummary":164,"conditions":175,"keywords":12,"overallStatus":44,"whyStopped":12,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"The control group","NO_INTERVENTION","Patients in the control group would go through observation and follow-up after recurrent endoscopic surgery.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"The experimental group","EXPERIMENTAL","Patients in the experimental group would be implemented with adjuvant therapy including chemotherapy and immunotherapy after endoscopic surgery.",[18,19],"Drug: Immunotherapy,Toripalimab Injection","Drug: Chemotherapy,Gemcitabine based regimen",[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":12},"DRUG","Immunotherapy,Toripalimab Injection","Patients in the experimental group would be implemented with adjuvant Immunotherapy and chemotherapy after endoscopic surgery. Four to six cycles chemotherapy and 10 cycles immunotherapy,or until unacceptable side effects.",[14],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":12},"Chemotherapy,Gemcitabine based regimen",[14],[30],{"name":31,"affiliation":32,"role":33},"Hongmeng Yu","Eye& ENT Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":12,"email":39},"Xiaole Song, MD","CONTACT","+8621 64377134","jxfxsxl@163.com",{"name":41,"role":37,"phone":12,"phoneExt":12,"email":12},"Yuting Lai",[43,66,81,95,110,121,134],{"facility":32,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Shanghai","Shanghai Municipality","200031","China","CN",{"type":51,"coordinates":52},"Point",[53,54],121.45806,31.22222,{"lat":54,"lon":53},[57,60,61,63,65],{"name":58,"role":37,"phone":59,"phoneExt":12,"email":39},"Xiaole Song","15821388769",{"name":31,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":58,"role":62,"phone":12,"phoneExt":12,"email":12},"SUB_INVESTIGATOR",{"name":64,"role":62,"phone":12,"phoneExt":12,"email":12},"Li Yan",{"name":41,"role":62,"phone":12,"phoneExt":12,"email":12},{"facility":67,"status":68,"city":69,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Fujian Medical University Union Hospital","NOT_YET_RECRUITING","Fuzhou",{"type":51,"coordinates":71},[72,73],119.30611,26.06139,{"lat":73,"lon":72},[76,78,79],{"name":77,"role":37,"phone":12,"phoneExt":12,"email":12},"Desheng Wang",{"name":77,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":80,"role":62,"phone":12,"phoneExt":12,"email":12},"Haichun Lai",{"facility":82,"status":44,"city":83,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"The People's Hospital of Guangxi Zhuang Autonomous Region","Nanning",{"type":51,"coordinates":85},[86,87],108.31667,22.81667,{"lat":87,"lon":86},[90,92,93],{"name":91,"role":37,"phone":12,"phoneExt":12,"email":12},"Shenhong Qu",{"name":91,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":94,"role":62,"phone":12,"phoneExt":12,"email":12},"Jingjin Weng",{"facility":96,"status":44,"city":45,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":97,"geoPoint":99,"contacts":100},"Changhai Hospital",{"type":51,"coordinates":98},[53,54],{"lat":54,"lon":53},[101,103,104,106,108],{"name":102,"role":37,"phone":12,"phoneExt":12,"email":12},"Haihong Tang",{"name":102,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":105,"role":62,"phone":12,"phoneExt":12,"email":12},"Hongliang Zheng",{"name":107,"role":62,"phone":12,"phoneExt":12,"email":12},"Haopu Li",{"name":109,"role":62,"phone":12,"phoneExt":12,"email":12},"Fengya Pan",{"facility":111,"status":68,"city":45,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"Shanghai Sixth People's Hospital",{"type":51,"coordinates":113},[53,54],{"lat":54,"lon":53},[116,118,119],{"name":117,"role":37,"phone":12,"phoneExt":12,"email":12},"Weitian Zhang",{"name":117,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":120,"role":62,"phone":12,"phoneExt":12,"email":12},"Ru Tang",{"facility":122,"status":68,"city":45,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":123,"geoPoint":125,"contacts":126},"Shanghai Zhongshan Hospital",{"type":51,"coordinates":124},[53,54],{"lat":54,"lon":53},[127,129,130,132],{"name":128,"role":37,"phone":12,"phoneExt":12,"email":12},"Xinsheng Huang",{"name":128,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":131,"role":33,"phone":12,"phoneExt":12,"email":12},"Xianhui Ning",{"name":133,"role":33,"phone":12,"phoneExt":12,"email":12},"Lei Zhou",{"facility":135,"status":68,"city":136,"state":12,"zip":12,"country":48,"countryCode":49,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Shenzhen Second People's Hospital","Shenzhen",{"type":51,"coordinates":138},[139,140],114.0683,22.54554,{"lat":140,"lon":139},[143,145,146],{"name":144,"role":37,"phone":12,"phoneExt":12,"email":12},"Yongtian Lu",{"name":144,"role":33,"phone":12,"phoneExt":12,"email":12},{"name":147,"role":33,"phone":12,"phoneExt":12,"email":12},"Jing Tao",{"type":149,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[151,152,154,155,156,158],{"name":122,"class":6},{"name":153,"class":6},"Shanghai 6th People's Hospital",{"name":96,"class":6},{"name":67,"class":6},{"name":157,"class":6},"People's Hospital of Guangxi Zhuang Autonomous Region",{"name":135,"class":6},"100533612","phase-3-adjuvant-vs-surgery-only-in-early-stage-recurrent-npc-100533612",false,"NCT06228079","Adjuvant vs Surgery Only in Early-stage Recurrent NPC","Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Pathologically diagnosed with recurrent nasopharyngeal carcinoma;\n2. Stage rT1 or rT2(superficial parapharyngeal space, distance to internal carotid artery \\>5mm)or rT3 (confined to the bottom wall of the sphenoid sinus),according to AJCC 8th edition;\n3. Cervical lymph node metastasis can be controlled locally\n4. Age 18 to 75 years;\n5. Without distant metastasis;\n6. Informed consent forms signed;\n7. ≥6months from the accomplishment of radiation to recurrence\n8. previously radiotherapy for only 1 course;\n9. ECOG score 0-2 and can tolerate chemotherapy and immunotherapy\n10. Sufficient organ function;\n11. Undergone endoscopic surgery with negative pathological margin;\n\nExclusion Criteria:\n\n1. Participation in other interventional clinical trials;\n2. Uncontrolled illnesses which will interfere with the ability to undergo therapy;\n3. Suffering from another or multiple malignancy within 5 years (excluding fully treated basal cell or skin squamous cell carcinoma, cervical carcinoma in situ);\n4. Any contradiction to immune and chemotherapy;\n5. With serious autoimmune disease;\n6. Currently usage of immunosuppressive agents or systemic glucocorticoid therapy (dosage\\>10mg\u002Fday prednisone or other glucocorticoids), and continuing to use them within 2 weeks before the first administration of trial drugs;\n7. Severe allergic reactions to other monoclonal antibodies;\n8. History of radioactive particle planting;\n9. Vaccination with live vaccine within 4 weeks prior to initial administration or possibly during the study period;\n10. Female patients who are at pregnancy or lactation;\n11. Other situations that the researchers believe are not suitable for enrollment","ALL","18 Years","75 Years",{"count":170,"type":171},176,"ESTIMATED","INTERVENTIONAL",[174],"PHASE3",[176],"Recurrent Nasopharyngeal Carcinoma","2025-07-01",{"date":179,"type":180},"2025-07-04","ACTUAL",{"date":182,"type":180},"2024-06-25",{"date":184,"type":171},"2028-06-30",{"name":5,"class":6},7]